Patent AU-2009217425-B2 (AU)
Title: Vaccine
Inventor: BOS MARTINE PETRONELLO
IPC: C07K14/22
Filed: 2009-03-06
Granted: 2014-10-23
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization IN International Bureau (43) International Publication Date H(10) International Publication Number 11 March 2010 (11.03.2010) PCT W O 2010/025964 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 39/095 (2006.01) C07K 14/22 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, PCT/EP2009/052689 EC, EE, EG, ES, Fl, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, 6 March 2009 (06.03.2009) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, (25) Filing Language: English NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, (26) Publication Language: English SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 0816447.7 8 September 2008 (08.09.2008) GB (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicants (for all designated States except US): GLAX- GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, OSMITHKLINE BIOLOGICALS S.A. [BE/BE]; rue ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, de l'Institut 89, B-1330 Rixensart (BE). UTRECHT TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, UNIVERSITY [NL/NL]; Department of Molecular and ES, Fl, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Cell Biology and Institute of Biomembranes, Padualaan 8, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), NL-3584 CH Utrecht (NL). OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, (72) Inventors; and MR, NE, SN, TD, TG). (75) Inventors/Applicants (for US only): BOS, Martine Declarations under Rule 4.17: Petronella [NL/NL]; Utrecht University, Padualaan 8' - as to applicant's entitlement to apply for and be granted NL-3584 CH Utrecht (NL). POOLMAN, Jan [NL/BE]; a t appl enii)) GlaxoSmithKline Biologicals s.a., rue de l'Institut 89, a patent (Rule 4.17(iip B-1330 Rixensart (BE). STORK, Michiel [NL/NL]; - as to the applicant's entitlement to claim the priority of Utrecht University, Padualaan 8, NL-3584 CH Utrecht the earlier application (Rule 4.17(iii)) (NL). TOMMASSEN, Johannes Petrus Maria - oinventorshi Rule 4.17(iv [NL/NL]; Utrecht University, Padualaan 8, NL-3584 CH SmithKline Biologicals s.a., rue de lInstitut 89, B-1330 novelty (Rule 4.17(v)) Rixensart (BE). Published: (74) Agents: LUBIENSKI, Michael John et al.; Glaxo- with international search report (Art. 21(3)) SmithKline, Corporate Intellectual Property CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB). (54) Title: VACCINE COMPRISING PROTEIN NMB0964 FROM MEISSERIA MENINGITIDIS f4 (57) Abstract: The present invention relates to immunogenic compositions comprising neisserial blebs with upregulated levels of the NMB0964 antigens such that bactericidal antibodies are generated against said antigen. It has been found for the first time that this antigen's expression is zinc regulated and therefore methods are provided to upregulated expression through removal of the zinc repression mechanism of the cell or promoter, or through removal of zinc from the culture medium.